| 英文别名 |
LXS196;Darovasertib;LXS196;IDE196;NVP-LXS196;3-amino-N-[3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide;Q29213686;SCHEMBL17506262;LXS-196?;NSC-800030;W39;EX-A2690;NVP-LXS-196;2-Pyrazinecarboxamide, 3-amino-N-(3-(4-amino-4-methyl-1-piperidinyl)-2-pyridinyl)-6-(3-(trifluoromethyl)-2-pyridinyl)-;CS-7529;LXS-196;Darovasertib (USAN);CHEMBL3982723;s6723;Example 9 [WO2016020864A1];Darovasertib [USAN];ZB1591;BCP20781;ZZC27676;1874276-76-2;GTPL11186;NSC800030;Example 9 (WO2016020864A1);AKOS040758778;BDBM251460;UNII-E0YF0M8O09;D85524;(6M)-3-amino-N-[3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide;Protein Kinase C Inhibitor LXS196;DAROVASERTIB [INN];PKC Inhibitor IDE196;AC-36337;D12139;IDE 196;DA-52316;E0YF0M8O09;3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide;IDE196;IDE-196;Protein Kinase C Inhibitor IDE196;HY-101569;C22H23F3N8O;US9452998, 9;WS-01966;DAROVASERTIB [WHO-DD];Darovasertib (LXS-196) |